Activist DOMA Perpetual Demands CEO Removal, Strategic Sale Amidst Proxy Battle
PCRX sits 22% above its 52-week low of $18.8 on light trading volume (0.2× avg).
Summary
Activist investor DOMA Perpetual has intensified its proxy battle against Pacira BioSciences, calling for the removal of CEO Frank Lee and a strategic sale of the company, citing gross negligence and value destruction.
Key Events · Ownership and Investor Activity · PCRX
-
Activist Proxy Battle Escalates
DOMA Perpetual (7.5% stake) has issued a definitive proxy statement and letter, urging shareholders to vote for its three director nominees at the June 9, 2026 Annual Meeting.
-
Demand for CEO Removal & Strategic Sale
DOMA proposes removing current CEO Frank Lee, appointing an interim CEO, and exploring a strategic sale of the company, particularly its core asset EXPAREL.
-
Accusations of Gross Negligence
DOMA alleges the board and management are misleading investors about significant patent risks for EXPAREL, citing a prior settlement that cost a third of future revenues.
-
Criticism of Financial Performance & Compensation
The activist highlights weak revenue growth (4% in 2025 vs. double-digit target), increased expenses, and CEO Frank Lee's $28 million compensation over two years while the company reported a negative $93 million net income.
Analysis · PCRX · Life Sciences
Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake, has escalated its proxy battle by issuing a detailed letter to shareholders. The letter accuses Pacira's board and management of gross negligence, misleading investors about critical patent risks for its core product EXPAREL, and value destruction through weak growth and excessive executive compensation. DOMA is pushing for the removal of CEO Frank Lee, the appointment of an interim CEO, and a strategic sale of the company to maximize shareholder value. This filing highlights a deep rift in corporate governance and presents a clear alternative strategy that could fundamentally alter the company's future.
At the time of this filing, PCRX was trading at $23.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $904.9M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.